Mobile Menu

BioInfi: Build and optimise a biotech portfolio: Target selection and disease indications

Pankaj Agarwal, Computational Biologist at BioInfi, shared in his D4 USA presentation in October last year how to build and optimise a biotech portfolio through target selection and indication expansion.

Following a lack of efficacy, the leading causes of clinical trial failure are poor target selection and poor patient selection/stratification. Therefore, Pankaj shares target features that translate into clinically successful drugs, examining AI and ML-based methods including deep learning, network diffusion and tensor factorization.

In his presentation, Pankaj also shares examples of systematic drug repurposing to identify new indications for active and terminated assets. The two methods provided are through GWAS studies and the use of connectivity maps.

Pankaj Agarwai - BioInfi

More on these topics

Drug Repurposing / ML / Target Selection

Share this article